To better characterize altered signaling pathways in Smarcb1 deficient tumor cells, which may contribute to the transformation process and to AKT activation, we conducted an unbiased quantitative phospho-proteomic analysis designed to identify differentially phosphorylated peptides between Smarcb1 proficient and deficient tumor cells. This evidence concerns the gene SMARCB1 and neoplasm.